Study of a new drug for pulmonary hypertension with lung disease
Part of Lungs & breathing clinical trials.
This trial tests an investigational drug called LAM-001 for people who have pulmonary hypertension (high blood pressure in the lungs) along with a type of lung disease called interstitial lung disease. The drug may help improve symptoms and daily function. This study will see if the drug is safe and helpful for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 85 years old.
- You have been diagnosed with pulmonary hypertension and interstitial lung disease (including certain types like IPF or hypersensitivity pneumonitis).
- You have had a right heart catheterization that shows high blood pressure in the lungs that is not due to left heart problems.
- You are able to walk at least 100 meters in 6 minutes.
- You are in WHO functional class II or III (meaning you have symptoms but are not bedridden).
- You have not smoked, vaped, or used marijuana within the last 90 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called TX000045 for people who have both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug can help improve breathing and daily function.
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
This trial tests a new treatment called L606 for people who have both a type of lung disease (ILD) and high blood pressure in the lungs (PH). The goal is to see if it is safe and helps with exercise and breathing.
This study tests an investigational medicine called LTP001 for pulmonary arterial hypertension (PAH). Part A checks safety in healthy volunteers, and Part B tests if it helps people with PAH by improving blood flow in the lungs.
This trial tests an investigational drug called NS-863 for people with pulmonary hypertension (high blood pressure in the lungs) that is caused by interstitial lung disease (scarring of the lungs). The study will check if the drug is safe and effective in improving your condition.
This study tests an investigational drug (HS235) for people who have both heart failure with preserved ejection fraction and a type of pulmonary hypertension that can happen with it. The goal is to see if the drug can improve symptoms and quality of life.
Hear when a new Pulmonary Hypertension Due to Lung Diseases and Hypoxia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.